Johann Wolfgang Goethe-universitat Frankfurt Am Main

The General Hospital Corporation

Sanofi-a Ventis Deutschland Gmbh

Johann Wolfgang Goethe-universitat

Horizon Pharma Ag

Irmgard Tegeder

Gerd Geisslinger

Clifford J Woolf

Martin Michaelis

Klaus Scholich

Michael Costigan

Robert Griffin

Keith M Channon

Jörn Lötsch

The invention relates to the use of a granulin or a granulin-like compound for producing a pharmaceutical composition for the therapy or prophylaxis of chronic pain, in particular for neuropathic pain.

Use of a granulin or a granulin-like compound for the therapy or prophylaxis of chronic pain

Use of a granulin or a granulin-like compound in the therapy or prophylaxis of chronic pains

The present invention features methods and compositions for preventing, reducing, or treating a traumatic, metabolic or toxic peripheral nerve lesion or pain including, for example, neuropathic pain, inflammatory and nociceptive pain by administering to a mammal in need thereof a compound that reduces the expression or activity of BH4. According to this invention, this reduction may be achieved by reducing the enzyme activity of any of the BH4 synthetic enzymes, such as GTP cyclohydrolase (GTPCH), sepiapterin reductase (SPR), or dihydropteridine reductase (DHPR); by antagonizing the cofactor function of BH4 on BH4-dependent enzymes; or by blocking BH4 binding to membrane bound receptors. The compounds of the invention may be administered alone or in combination with a second therapeutic agent.

Methods for treating pain

Growing community of inventors

Frankfurt-am-Main, Germany

Irmgard Tegeder